Total Payments
$374,919
2024 Payments
$29,250
Companies
18
Transactions
411
Medicare Patients
671
Medicare Billing
$217,915
Payment Breakdown by Category
Other$175,395 (46.8%)
Consulting$140,467 (37.5%)
Travel$39,167 (10.4%)
Research$13,404 (3.6%)
Food & Beverage$6,487 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $174,545 | 49 | 46.6% |
| Consulting Fee | $140,467 | 51 | 37.5% |
| Travel and Lodging | $39,167 | 168 | 10.4% |
| Unspecified | $13,404 | 17 | 3.6% |
| Food and Beverage | $6,487 | 125 | 1.7% |
| Honoraria | $850.00 | 1 | 0.2% |
Payments by Type
General
$361,515
394 transactions
Research
$13,404
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $137,201 | 128 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $82,622 | 118 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $43,029 | 39 | $0 (2024) |
| Gilead Sciences, Inc. | $26,197 | 33 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $18,333 | 12 | $0 (2024) |
| ABBVIE INC. | $15,728 | 19 | $0 (2024) |
| Celgene Corporation | $14,796 | 18 | $0 (2023) |
| ADC Therapeutics America, Inc. | $10,775 | 8 | $0 (2024) |
| BeiGene USA, Inc. | $6,500 | 1 | $0 (2020) |
| Genentech USA, Inc. | $4,446 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,250 | 40 | ABBVIE INC. ($13,703) |
| 2023 | $44,095 | 46 | Kite Pharma, Inc. ($16,266) |
| 2022 | $31,217 | 27 | ADC Therapeutics America, Inc. ($8,742) |
| 2021 | $23,127 | 16 | Kite Pharma, Inc. ($16,379) |
| 2020 | $25,090 | 16 | Kite Pharma, Inc. ($6,610) |
| 2019 | $95,595 | 115 | Kite Pharma, Inc. ($41,606) |
| 2018 | $101,483 | 115 | Kite Pharma, Inc. ($51,265) |
| 2017 | $25,062 | 36 | Bayer HealthCare Pharmaceuticals Inc. ($19,891) |
All Payment Transactions
411 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $669.89 | Research |
| Study: 2L ASCT eligible study in DLBCL glofit R ICE | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $562.85 | Research |
| Study: 2L ASCT eligible study in DLBCL glofit R ICE | ||||||
| 12/31/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| 12/07/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $61.99 | General |
| Category: BioOncology | ||||||
| 12/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $113.34 | General |
| Category: Oncology | ||||||
| 12/06/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $72.93 | General |
| 10/09/2024 | Genentech USA, Inc. | Polivy (Biological), Columvi, Lunsumio | Consulting Fee | Cash or cash equivalent | $2,660.00 | General |
| Category: BioOncology | ||||||
| 09/06/2024 | ABBVIE INC. | EPKINLY (Drug) | Consulting Fee | Cash or cash equivalent | $725.00 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $902.80 | Research |
| Study: CYTB323A12101 | ||||||
| 07/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| 07/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $725.00 | General |
| 07/17/2024 | ABBVIE INC. | EPKINLY (Drug) | Consulting Fee | Cash or cash equivalent | $725.00 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $29.77 | General |
| Category: BioOncology | ||||||
| 06/06/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,520.00 | General |
| 06/02/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $40.56 | General |
| Category: BioOncology | ||||||
| 05/31/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Consulting Fee | Cash or cash equivalent | $3,037.50 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $90.00 | General |
| Category: Oncology | ||||||
| 04/25/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $668.62 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $650.58 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $121.22 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $10.01 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| KYMRIAH Study Related Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $7,228 | 1 |
| CTL019B2401 | Novartis Pharmaceuticals Corporation | $1,391 | 1 |
| 2L ASCT eligible study in DLBCL glofit R ICE | F. Hoffmann-La Roche AG | $1,233 | 2 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001), A Phase 2 study of JCAR017 as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL & OUTREACH 3L+ LBCL 017007 (017001, 017006, 017007) | Celgene Corporation | $935.00 | 1 |
| CYTB323A12101 | Novartis Pharmaceuticals Corporation | $902.80 | 1 |
| CCTL019E2202 | Novartis Pharmaceuticals Corporation | $638.48 | 1 |
| A PHASE II SINGLE ARM MULTICENTER OPEN LABEL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN ADULT PATIENTS WITH REFRACTORY OR RELAPSED FOLLICULAR LYMPHOMA | Novartis Pharmaceuticals Corporation | $355.00 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $336.00 | 2 |
| A Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in high risk 1st Line DLBCL | Gilead Sciences, Inc. | $275.21 | 6 |
| A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | Kite Pharma, Inc. | $108.81 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 153 | 509 | $262,333 | $53,306 |
| 2022 | 4 | 152 | 457 | $230,261 | $47,629 |
| 2021 | 5 | 166 | 522 | $241,620 | $58,259 |
| 2020 | 7 | 200 | 577 | $240,023 | $58,720 |
Total Patients
671
Total Services
2,065
Medicare Billing
$217,915
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 90 | 259 | $161,630 | $30,174 | 18.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 189 | $78,618 | $18,792 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 36 | 61 | $22,085 | $4,340 | 19.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 86 | 248 | $145,466 | $29,426 | 20.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 146 | $58,708 | $12,527 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 33 | 52 | $17,504 | $3,842 | 21.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $8,583 | $1,834 | 21.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 85 | 250 | $145,072 | $31,025 | 21.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 172 | $65,653 | $14,443 | 22.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 12 | 47 | $7,802 | $7,527 | 96.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 28 | 39 | $12,597 | $2,981 | 23.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 14 | $10,496 | $2,283 | 21.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 69 | 230 | $127,643 | $21,934 | 17.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 19 | 89 | $14,774 | $14,215 | 96.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 154 | $57,511 | $13,887 | 24.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 38 | 54 | $16,914 | $3,317 | 19.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 17 | 17 | $12,423 | $2,814 | 22.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 16 | 21 | $6,207 | $1,445 | 23.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 11 | 12 | $4,551 | $1,108 | 24.4% |
About Peter Riedell
Peter Riedell is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2010. The National Provider Identifier (NPI) number assigned to this provider is 1265753834.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Peter Riedell has received a total of $374,919 in payments from pharmaceutical and medical device companies, with $29,250 received in 2024. These payments were reported across 411 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($174,545).
As a Medicare-enrolled provider, Riedell has provided services to 671 Medicare beneficiaries, totaling 2,065 services with total Medicare billing of $217,915. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 06/18/2010
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1265753834
Products in Payments
- Yescarta (Drug) $132,239
- Aliqopa (Drug) $64,987
- KYMRIAH (Biological) $17,908
- Non-Covered $17,519
- Tecartus (Drug) $16,315
- KYMRIAH (Drug) $12,386
- Zydelig (Drug) $7,734
- Revlimid (Drug) $7,366
- BRUKINSA (Drug) $6,500
- IMBRUVICA (Drug) $6,084
- Epkinly (Drug) $3,617
- Polivy (Biological) $2,763
- EPKINLY (Drug) $2,192
- clonoSEQ (Device) $1,544
- TASIGNA (Drug) $940.01
- JCAR017 (Drug) $935.00
- XPOVIO (Drug) $850.00
- VENCLEXTA (Drug) $823.68
- Vitrakvi (Drug) $115.62
- Columvi (Biological) $84.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678
Randy Sweis
Hematology & Oncology — Payments: $346,946
Hematology & Oncology $346,946